

					
						November 4, 2017 - By Marie Mckinney
 Evoke Pharma Incorporated (NASDAQ:EVOK) had an increase of 17.98% in short interest. EVOK’s SI was 1.10M shares in November as released by FINRA. Its up 17.98% from 931,700 shares previously. With 192,700 avg volume, 6 days are for Evoke Pharma Incorporated (NASDAQ:EVOK)’s short sellers to cover EVOK’s short positions. The SI to Evoke Pharma Incorporated’s float is 11.39%. The stock decreased 0.70% or $0.02 on November 3, reaching $2.82. About 84,878 shares traded. Evoke Pharma Inc (NASDAQ:EVOK) has declined 51.99% since November 4, 2016 and is downtrending. It has underperformed by 68.69% the S&P500.Eqis Capital Management Inc increased China Pete & Chem Corp (SNP) stake by 48.45% reported in 2017Q2 SEC filing. Eqis Capital Management Inc acquired 4,614 shares as China Pete & Chem Corp (SNP)’s stock rose 4.36%. The Eqis Capital Management Inc holds 14,137 shares with $1.11 million value, up from 9,523 last quarter. China Pete & Chem Corp now has $107.25 billion valuation. The stock decreased 1.30% or $0.97 on November 3, reaching $73.58. About 113,043 shares traded. China Petroleum & Chemical Corp (ADR) (NYSE:SNP) has risen 24.29% since November 4, 2016 and is uptrending. It has outperformed by 7.59% the S&P500.Investors sentiment decreased to 1.5 in Q2 2017. Its down 3.83, from 5.33 in 2017Q1. It is negative, as 1 investors sold Evoke Pharma Inc shares while 3 reduced holdings. 1 funds opened positions while 5 raised stakes. 1.88 million shares or 44.66% less from 3.40 million shares in 2017Q1 were reported. Bancorp Of America Corporation De has invested 0% of its portfolio in Evoke Pharma Inc (NASDAQ:EVOK). Wells Fargo & Mn has 5,000 shares for 0% of their portfolio. Moreover, Blackrock has 0% invested in Evoke Pharma Inc (NASDAQ:EVOK). State Treasurer State Of Michigan invested in 400,000 shares or 0.01% of the stock. Morgan Stanley has 0% invested in Evoke Pharma Inc (NASDAQ:EVOK). California Employees Retirement Sys owns 0% invested in Evoke Pharma Inc (NASDAQ:EVOK) for 36,700 shares. Family Mngmt stated it has 10,425 shares. Art Limited Liability Company holds 15,413 shares or 0% of its portfolio. Bancorp Of Mellon Corp has 24,908 shares for 0% of their portfolio. Pnc Financial Services Grp owns 18,000 shares or 0% of their US portfolio. Utd Capital Advisers Lc reported 15,566 shares. Sphera Funds Mngmt has 500,000 shares for 0.22% of their portfolio. Deutsche Bancshares Ag holds 0% of its portfolio in Evoke Pharma Inc (NASDAQ:EVOK) for 200 shares. Northern Tru, Illinois-based fund reported 29,214 shares. 523,650 are held by Vanguard Group.Among 9 analysts covering Evoke Pharma (NASDAQ:EVOK), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Evoke Pharma had 17 analyst reports since August 20, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Northland Capital on Wednesday, March 16. As per Tuesday, October 24, the company rating was maintained by H.C. Wainwright. The stock of Evoke Pharma Inc (NASDAQ:EVOK) earned “Buy” rating by H.C. Wainwright on Tuesday, August 15. Rodman & Renshaw downgraded it to “Neutral” rating and $2 target in Monday, July 18 report. On Tuesday, July 19 the stock rating was downgraded by Noble Financial to “Hold”. The firm earned “Buy” rating on Monday, March 14 by Ascendiant Capital. The firm has “Buy” rating given on Thursday, January 5 by Rodman & Renshaw. The firm has “Neutral” rating given on Friday, December 23 by Rodman & Renshaw. The rating was initiated by Brean Capital on Thursday, August 20 with “Buy”. As per Friday, October 2, the company rating was initiated by Rodman & Renshaw.Evoke Pharma, Inc. is a specialty pharmaceutical company. The company has market cap of $43.40 million. The Firm is focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. It currently has negative earnings. The Firm is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.Among 5 analysts covering China Petroleum & Chemical Corp (NYSE:SNP), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. China Petroleum & Chemical Corp had 7 analyst reports since August 26, 2015 according to SRatingsIntel. HSBC upgraded the stock to “Hold” rating in Wednesday, August 26 report. The rating was upgraded by Jefferies on Friday, September 11 to “Hold”. Mizuho upgraded the stock to “Buy” rating in Wednesday, March 2 report. The stock of China Petroleum & Chemical Corp (ADR) (NYSE:SNP) earned “Neutral” rating by Macquarie Research on Thursday, November 12. The stock of China Petroleum & Chemical Corp (ADR) (NYSE:SNP) earned “Buy” rating by Jefferies on Wednesday, September 30. The stock of China Petroleum & Chemical Corp (ADR) (NYSE:SNP) has “Sell” rating given on Friday, August 28 by Citigroup. On Tuesday, March 29 the stock rating was downgraded by Credit Suisse to “Neutral”.Eqis Capital Management Inc decreased Ishares Iboxx $ High Yield Corporate Bon (HYG) stake by 15,032 shares to 373,755 valued at $33.04 million in 2017Q2. It also reduced Unitedhealth Group (NYSE:UNH) stake by 1,650 shares and now owns 5,521 shares. Dow Chem Co (NYSE:DOW) was reduced too.  - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.By Marie Mckinney